RAPT Therapeutics Announces Proposed Offering of Common Stock
February 04 2020 - 5:43PM
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage
immunology-based biopharmaceutical company focused on discovering,
developing and commercializing oral small molecule therapies for
patients with significant unmet needs in oncology and inflammatory
diseases, today announced that it has commenced an underwritten
public offering of 2,000,000 shares of its common stock. The
Company expects to grant the underwriters a 30-day option to
purchase up to an additional 300,000 shares of common stock sold in
connection with the offering. All of the shares in the offering
will be sold by RAPT. The proposed offering is subject to
market and other conditions, and there can be no assurances as to
whether or when the proposed offering may be completed, or as to
the actual size or terms of the proposed offering.
BMO Capital Markets, Wells Fargo Securities, UBS
Investment Bank and Cantor Fitzgerald & Co. are acting as joint
book-running managers for the offering.
A registration statement related to the offering
has been filed with the Securities and Exchange Commission but has
not yet become effective.
The offering is being made only by means of a
prospectus. A copy of the preliminary prospectus relating to this
offering may be obtained from: BMO Capital Markets Corp.,
Attention: Equity Syndicate Department, 3 Times Square, 25th Floor,
New York, NY 10036, by telephone at (800) 414-3627 or by e-mail at
bmoprospectus@bmo.com; Wells Fargo Securities, LLC, Attention:
Equity Syndicate Department, 500 West 33rd Street, New York, New
York 10001, or by email at cmclientsupport@wellsfargo.com, or by
telephone at (800) 326-5897; UBS Securities LLC, Attention:
Prospectus Department, 1285 Avenue of the Americas, New York, NY
10019, by telephone at (888) 827-7275 or by email at
ol-prospectus-request@ubs.com; or Cantor Fitzgerald & Co.,
Attention: Capital Markets, 499 Park Avenue, 6th Floor, New York,
New York 10022, or by email at prospectus@cantor.com.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy these securities, nor
shall there be any sale of these securities in any state or other
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such state or other jurisdiction.
About RAPT Therapeutics,
Inc.
RAPT Therapeutics is a clinical stage
immunology-based biopharmaceutical company focused on discovering,
developing and commercializing oral small molecule therapies for
patients with significant unmet needs in oncology and inflammatory
diseases. Utilizing its proprietary discovery and development
engine, the Company is developing highly selective small molecules
designed to modulate the critical immune drivers underlying these
diseases. RAPT has discovered and advanced two unique drug
candidates, FLX475 and RPT193, each targeting C-C motif chemokine
receptor 4, for the treatment of cancer and inflammation,
respectively. The Company is also pursuing a range of targets,
including general control nonderepressible 2 (GCN2) and
hematopoietic progenitor kinase 1 (HPK1), that are in the discovery
stage of development.
Media Contact:Angela
Bittingmedia@rapt.com (925) 202-6211
Investor Contact:Sylvia
Wheelerswheeler@wheelhouselsa.com
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Apr 2023 to Apr 2024